
Associate Professor
Pediatrics
Dr. Farzana Perwad is a specialist who cares for children with kidney disease, including those requiring dialysis and kidney transplant. Her expertise includes evaluating and treating chronic kidney disease in children, nephrotic syndrome (a disorder that causes excessive excretion of protein in the urine), kidney stones, urinary tract infections, and kidney or urinary tract abnormalities that were present at birth. Her research focus is to understand the molecular mechanisms of regulation of phosphorus and vitamin D metabolism in the setting of chronic kidney disease.
Interests: FGF23, kidney, phosphorus, calcium, vitamin D, rickets, chronic kidney disease, bone, PTH
Publications
ASN Kidney Health Guidance on Potassium and Phosphorus Food Additives.
Journal of the American Society of Nephrology : JASN
Network Interactions of Circulating FGF23, HRG-HMGB1, and Cardiac Disease in CKD.
Journal of the American Society of Nephrology : JASN
Association of the Ratio of Intact-to-C-terminal Fibroblast Growth Factor 23 with Heart Failure with Preserved Ejection Fraction.
Journal of the American Society of Nephrology
Transfer Learning Predicts Network Biology for Fibroblast Growth Factor 23 (FGF-23) and Cardiac Disease.
Journal of the American Society of Nephrology
Multi-trait Analysis of GWAS for circulating FGF23 Identifies Novel Network Interactions Between HRG-HMGB1 and Cardiac Disease in CKD.
medRxiv : the preprint server for health sciences
Multi-Trait Analysis of Mineral Metabolism Markers Identifies Novel Genetic Associations for FGF23.
Journal of the American Society of Nephrology
Multi-Trait Genome-Wide Association Study (GWAS) and Functional Genomics Identifies Novel Genetic Traits and Dynamic Networks for FGF23.
Journal of the American Society of Nephrology
Burosumab Versus Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Sub-group Analysis by Dose Level.
The Journal of clinical endocrinology and metabolism
Genetic testing in children with nephrolithiasis and nephrocalcinosis.
Pediatric nephrology (Berlin, Germany)
Genetic Variants Associated with Mineral Metabolism Traits in Chronic Kidney Disease.
The Journal of clinical endocrinology and metabolism
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Calcified tissue international
Rickets in a child with prolonged acquired hypothyroidism secondary to Hashimoto's thyroiditis.
Endocrinology, diabetes & metabolism case reports
Association of Genetically Predicted Fibroblast Growth Factor-23 with Heart Failure: A Mendelian Randomization Study.
Clinical journal of the American Society of Nephrology : CJASN
Genetic Testing in Children with Nephrolithiasis and Nephrocalcinosis.
Journal of the American Society of Nephrology
Longitudinal Changes in FGF-23 in Children with CKD.
Journal of the American Society of Nephrology
Adverse Consequences of Chronic Kidney Disease on Bone Health in Children.
Seminars in nephrology
Renal Dnase1 expression is regulated by FGF23 but loss of Dnase1 does not alter renal phosphate handling.
Scientific reports
Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia.
Calcified tissue international
Nephrocalcinosis at Baseline Did Not Increase the Risk of Nephrocalci-nosis Progression After Long-Term Burosumab Treatment in Adults and Children with X-Linked Hypophosphatemia (XLH).
Journal of the American Society of Nephrology
Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
Current opinion in nephrology and hypertension
OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial.
Journal of the Endocrine Society
Fibroblast growth factor 23 and phosphate homeostasis.
Current opinion in nephrology and hypertension
Risk Factors for Transplant-Associated Thrombotic Microangiopathy after Autologous Hematopoietic Cell Transplant in High-Risk Neuroblastoma.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Burosumab Therapy for X-Linked Hypophosphatemia and Therapeutic Implications for CKD.
Clinical journal of the American Society of Nephrology : CJASN
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Calcified tissue international
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Lancet (London, England)
Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation.
Kidney international
Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
The Journal of clinical investigation
Fibroblast Growth Factor 23 Expression Is Increased in Multiple Organs in Mice With Folic Acid-Induced Acute Kidney Injury.
Frontiers in physiology
Vitamin D and kidney disease.
Bone reports
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Monogenic Causes of Proteinuria in Children.
Frontiers in medicine
Autoimmune hyperphosphatemic tumoral calcinosis.
Bone Abstracts
Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
Clinical journal of the American Society of Nephrology : CJASN
Phosphate Homeostasis and Metabolic Bone Disease.
The Physiological Basis of Metabolic Bone Disease
Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.
Endocrinology
Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23.
Molecular and cellular endocrinology
Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Calcium and Phosphorus.
Pediatric Nephrology
Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.
American journal of physiology. Renal physiology
Vitamin D 1alpha-hydroxylase gene mutations in patients with 1alpha-hydroxylase deficiency.
The Journal of clinical endocrinology and metabolism
Custom Person Type